argenx combines the diversity of the llama immune system with antibody engineering to advance a clinical pipeline to treat patients with cancer and autoimmune diseases. Our platforms allow us to unlock novel and complex targets and develop antibody-based drugs designed for greater efficacy and longer duration of effect. The strength of our team, our deep understanding of the biology, and our committed collaborations with industry leaders contribute to the success of our journey.
argenx is listed on the Euronext Brussels exchange under the symbol ARGX.
argenx Address
Technologiepark 30 Zwijnaarde, null Belgium
argenx Email
Past Companies
argenxHead of Legal, US
Sunovion PharmaceuticalsAssociate General Counsel, Commercial and R&D
Alexion Pharmaceuticals, Inc.Executive Director, US Legal – Commercial and Medical Affairs